Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 3/20 | 0.38 |
| ▸ | CSF1R | P07333 | 10/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862001 | 0.83 | PTGES (0.42) | PIN1MAPT | |
| SCHEMBL3861256 | 0.76 | CSF1R (0.36) | PIN1CSF1RTHRBLRRK2CRHBP | |
| SCHEMBL3865236 | 0.74 | CRHBP (0.53) | PIN1CSF1RCRHBPCRHR2MAPT | |
| SCHEMBL3865918 | 0.74 | PIN1 (0.48) | PIN1CSF1RCRHBPCRHR2MAPT | |
| SCHEMBL5344692 | 0.73 | POLB (0.40) | PIN1MAPT | |
| SCHEMBL4157332 | 0.73 | PDE10A (0.40) | THRBMAPT | |
| SCHEMBL3862164 | 0.68 | CSF1R (0.41) | CSF1RTHRBLRRK2 | |
| SCHEMBL2244603 | 0.67 | PIN1 (0.48) | PIN1CRHBPCRHR2MAPT | |
| SCHEMBL2248311 | 0.67 | CRHBP (0.53) | PIN1CRHBPCRHR2MAPT | |
| SCHEMBL27994848 | 0.67 | POLB (0.43) | PIN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598382-B2 | Aryl substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | PIN1 1271/4885CSF1R 294/4885THRB 1937/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | PIN1 1271/4885CSF1R 294/4885THRB 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.